Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27253772
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Curr+Opin+Pulm+Med
2016 ; 22
(5
): 456-65
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Pharmacogenetics and interstitial lung disease
#MMPMID27253772
Oldham JM
; Noth I
; Martinez FJ
Curr Opin Pulm Med
2016[Sep]; 22
(5
): 456-65
PMID27253772
show ga
PURPOSE OF REVIEW: Interstitial lung disease (ILD) is comprised of a
heterogeneous group of disorders with highly variable natural histories and
response to therapies. Pharmacogenetics focuses on the variability in drug
response because of the presence of genetic factors that influence drug
metabolism or disease activity. In this article, we review relevant drug-specific
and disease-specific polymorphisms that may influence therapeutic response, and
then highlight a recently identified drug-gene interaction in patients with
idiopathic pulmonary fibrosis (IPF). RECENT FINDINGS: The emergence of
high-throughput genomic technology has allowed for identification of gene
polymorphisms associated with susceptibility to specific disease states,
including IPF and several connective tissue diseases known to cause ILD. IPF risk
loci span a diverse group of genes, while most associated with connective tissue
disease are critical to immune signaling. A recent pharmacogenetic analysis of
patients enrolled in an IPF clinical trial identified a variant within TOLLIP to
be associated with differential response to N-acetylcysteine therapy. SUMMARY:
Though few pharmacogenetic investigations have been conducted in patients with
ILD to date, ample opportunities for pharmacogenetic exploration exist in this
patient population. Such exploration will advance our understanding of specific
ILDs and help usher in an era of personalized medicine.
free
free
free
